中文简介
《胃癌杂志》（J胃癌）是一本国际同行评议的杂志。每一期都对胃肿瘤进行了高质量的临床和转化研究。J胃癌编委会发表胃癌病理生理学、分子肿瘤学、诊断、治疗和预防的原创文章，以及胃癌患者饮食控制和提高生活质量的文章。胃癌包括病例报告、评论文章、我如何做到这一点的文章、社论和致编辑的信。通过在线（https://jgc online.org）对提交的文章进行审查和筛选，减少了评估和发布的时间。有关提交的详细信息，请参阅“作者说明”。J胃癌致力于为胃癌的治疗提供新的信息，通过推广，提高公众健康水平。本杂志中的所有或部分文章都以KCI、Koreamed、Komci、Koreamed Synapse、PMC、Scopus为索引，并扩展了科学引文索引（Scie、科学网）。全文可从https://jgc-online.org获取。有关订阅和所有其他信息，请访问我们的网站（https://jgc online.org）。
英文简介
The Journal of Gastric Cancer (J Gastric Cancer) is an international peer-reviewed journal. Each issue carries high quality clinical and translational researches on gastric neoplasms. Editorial Board of J Gastric Cancer publishes original articles on pathophysiology, molecular oncology, diagnosis, treatment, and prevention of gastric cancer as well as articles on dietary control and improving the quality of life for gastric cancer patients. J Gastric Cancer includes case reports, review articles, how I do it articles, editorials, and letters to the editor. The process of review and screening of submitted articles is through online (https://jgc-online.org), which enable to decrease time for the assessment and publication. Please refer to "instructions for authors" for detailed information regarding submissions. J Gastric Cancer is dedicated to provide recent researches on new information for treating gastric cancer, by extension, to improve public health. All or some of the articles in this journal are indexed in KCI, KoreaMed, KoMCI, KoreaMed Synapse, PMC, Scopus, and Science Citation Index Expanded (SCIE, Web of Science). Full text is available from https://jgc-online.org. For subscription and all other information, visit our website (https://jgc-online.org).
近年期刊自引率趋势图
JCR分区
| JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
| Q3 | ONCOLOGY | Q3 | 3.197 |
| GASTROENTEROLOGY & HEPATOLOGY | Q3 |
近年期刊影响因子趋势图
CiteScore数值
| CiteScore | SJR | SNIP | 学科类别 | 分区 | 排名 | 百分位 |
| 4.40 | 0.716 | 1.226 | 大类：Medicine 小类：Gastroenterology | Q2 | 58 / 149 |
61% |
| 大类：Medicine 小类：Oncology | Q2 | 175 / 360 |
51% |
|||
| 大类：Medicine 小类：Cancer Research | Q3 | 137 / 210 |
35% |
